Qian Jiang, Zongru Li, Yanli Zhang, Yu Hu, WeiMing Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huangling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang. "Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations." Blood, 2025. doi:10.1182/blood-2025-3788